| Literature DB >> 33845462 |
Margaret A Tempero1, Mokenge P Malafa2, Mahmoud Al-Hawary3, Stephen W Behrman4, Al B Benson5, Dana B Cardin6, E Gabriela Chiorean7, Vincent Chung8, Brian Czito9, Marco Del Chiaro10, Mary Dillhoff11, Timothy R Donahue12, Efrat Dotan13, Cristina R Ferrone14, Christos Fountzilas15, Jeffrey Hardacre16, William G Hawkins17, Kelsey Klute18, Andrew H Ko1, John W Kunstman19, Noelle LoConte20, Andrew M Lowy21, Cassadie Moravek22, Eric K Nakakura1, Amol K Narang23, Jorge Obando9, Patricio M Polanco24, Sushanth Reddy25, Marsha Reyngold26, Courtney Scaife27, Jeanne Shen28, Charles Vollmer29, Robert A Wolff30, Brian M Wolpin31, Beth Lynn32, Giby V George32.
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.Entities:
Year: 2021 PMID： 33845462 DOI： 10.6004/jnccn.2021.0017
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908